Both the protein and mRNA of PD-L1 can be used to evaluate the tumor immunophenotype, and a high expression of PD-L1 generally predicts benefits from anti–PD1/PD-L1 therapy, resulting in a better prognosis (Conroy et al., 2019). This evidence concerns the gene PDCD1 and neoplasm.